Get the Stockscreener App
10.79
4.08%
0.4201
Phathom Pharmaceuticals Inc stock is traded at $10.79, with a volume of 210.14K.
It is up +4.08% in the last 24 hours and down -9.07% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$10.37
Open:
$10.32
24h Volume:
210.14K
Relative Volume:
0.17
Market Cap:
$860.57M
Revenue:
$204.89M
Net Income/Loss:
$-157.30M
P/E Ratio:
-5.1111
EPS:
-2.1111
Net Cash Flow:
$-97.76M
1W Performance:
+7.93%
1M Performance:
-9.07%
6M Performance:
-26.53%
1Y Performance:
+1.44%
1-Day Range:
$10.23
$10.82
1-Week Range:
$9.74
$10.82
52-Week Range:
$7.61
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
10.79 | 827.07M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
450.79 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.61 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
881.21 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.81 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.91 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-12-25 | Initiated | Raymond James | Strong Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals (PHAT) Surges 4.74% as Bullish Momentum BuildsBreakout Trade - newsline.com
Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Phathom: Why I’m Downgrading To "Sell" Ahead Of Competition (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference - Traders Union
(PHAT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Phathom Pharmaceuticals honors Tachi Yamada legacy in GI medicine - Traders Union
PHAT Stock Price, Quote & Chart | PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) - ChartMill
Phathom Pharmaceuticals (PHAT) Surges 4.44% as Stock Tests Key ResistanceWave Alternation - newsline.com
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs. - Pluang
[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Phathom Pharmaceuticals to engage investors at multiple conferences in May and June - Traders Union
How (PHAT) Movements Inform Risk Allocation Models - Stock Traders Daily
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Phathom Pharmaceuticals (PHAT) Slips 2.16% as Stock Tests Key Support LevelsOBV Divergence - thelegaladvocate.com
Hear Phathom at three upcoming healthcare investor conferences - Stock Titan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Phathom Shareholders Reaffirm Board, Pay and Auditor - The Globe and Mail
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Director Mark Stenhouse awarded 24,122 RSUs at Phathom (PHAT) - Stock Titan
Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs - Stock Titan
Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant - Stock Titan
Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan - Stock Titan
Director Theodore Schroeder (PHAT) receives 24,122 RSU award under non-employee plan - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes - Stock Titan
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - The Manila Times
Stomach drug vonoprazan draws 28 independent studies at DDW 2026 - Stock Titan
Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained - TipRanks
Trading Systems Reacting to (PHAT) Volatility - Stock Traders Daily
TradingKey - TradingKey
Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance
Why Phathom Pharmaceuticals (PHAT) might be the steady performer you need (Investor Interest) 2026-05-03Double EMA - newsline.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com Australia
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Q1 2026 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
1.35%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):